A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Ventricular Septal Defect Clinical Trial

Official title:
A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Status Recruiting

Clinical Trial Summary

This is a randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of L-citrulline versus placebo in patients undergoing surgery for congenital heart defects. Eligible patients undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment.

Clinical Trial Description

This is a randomized, double-blind, placebo controlled, multicenter study that will compare the efficacy and safety of L- citrulline versus placebo in patients undergoing surgery for congenital heart defects. Eligible patients undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment. Each enrolled patient will be randomized to receive either L citrulline or placebo throughout all administrations in the study. Patients will receive: 1. an L-citrulline bolus of 150 mg/kg or placebo at the initiation of cardiopulmonary bypass 2. the addition L-citrulline or placebo to maintain a steady state target concentration of approximately 100 μmol/L of L-Citrulline or placebo during cardiopulmonary bypass 3. an L-citrulline bolus of 10 mg/kg or placebo 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 µmol/L. The study drug or placebo infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first. Patients will be followed until Day 28 or discharge from the hospital, whichever occurs first. For patients discharged prior to Day 28, a final assessment via telephone will be conducted at Day 28. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05253209
Study type	Interventional
Source	Asklepion Pharmaceuticals, LLC
Contact	Gurdyal Kalsi, MD, MFPM
Phone	+1 410.736.3750
Email	gurdyal.kalsi@asklepionpharm.com
Status	Recruiting
Phase	Phase 3
Start date	June 29, 2022
Completion date	February 10, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03684161` - Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect
Completed	`NCT01120964` - Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol	Phase 1/Phase 2
Completed	`NCT02914652` - The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.	Phase 4
Recruiting	`NCT05939713` - Cera™ VSD Occluder Post Market Clinical Follow-up
Recruiting	`NCT06298344` - The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease	Early Phase 1
Recruiting	`NCT05688670` - Regional Anesthesia Following Pediatric Cardiac Surgery	Phase 4
Completed	`NCT02138435` - Longterm Outcome After Ventricular Septal Defect Closure	N/A
Completed	`NCT00556361` - Use of Ketamine Prior to Cardiopulmonary Bypass in Children	Phase 2
Completed	`NCT05200910` - The Effect of Transcatheter VSD Closure on Children's Appetite, Hormones and Growth
Recruiting	`NCT03127748` - Cardiac Function After Transcatheter VSD Closure	N/A
Enrolling by invitation	`NCT06214182` - Immune Heterogeneity Before and After Cardiopulmonary Bypass in Children
Active, not recruiting	`NCT04667455` - Improving Care for Children With Congenital Heart Disease.	N/A
Completed	`NCT04417712` - Lifetech KONAR MFO Post-Market Clinical Follow-Up Study
Completed	`NCT01313832` - The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension	N/A
Active, not recruiting	`NCT04017975` - Optical Tissue Identification for Myocardial Architecture	Phase 2
Completed	`NCT01915277` - A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics	Phase 1
Recruiting	`NCT03941691` - A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure	N/A
Completed	`NCT04859036` - The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.